REPLReplimune, Inc.Signing up patients
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Metastatic Uveal Melanoma
4Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +3.9
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 10, fading over time
Worry score4
Score over time
- Stage
- Phase 2/3
- Patients
- 280 (planned)
- Started
- Dec 17, 2024
- Main results expected
- Jan 2030
- Fully finished
- Oct 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: From Day 1 up to 3 years after last dose.
Progression Free Survival (PFS)
Measured over: From Day 1 up to 3 years after last dose.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 3.9, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06581406 · record last updated 2026-04-02 · checked 2026-11-09 15:42 UTC